What is the Share Price of Balaxi Pharmaceuticals Ltd?

Balaxi Pharmaceuticals Ltd share price is ₹585.00 As on 27 April, 2024|11:25

Home
>
Share Price
>
Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Ltd

Q: What is the Market Cap of Balaxi Pharmaceuticals Ltd?

The Market Cap of Balaxi Pharmaceuticals Ltd is ₹638 As on 27 April, 2024|11:25

Q: What is PE Ratio of Balaxi Pharmaceuticals Ltd?

The P/E ratio of Balaxi Pharmaceuticals Ltd is 18.4 As on 27 April, 2024|11:25

Q: What is PB Ratio of Balaxi Pharmaceuticals Ltd?

The PB ratio of Balaxi Pharmaceuticals Ltd is 12.58 As on 27 April, 2024|11:25

₹ 585.00 +0.80 (0.14%)
Updated on 27-04-2024 6:50 AM

Stock Rating

NSE

Pros 2

Cons 5

Price Performance

Day's Low
₹574.75

Day's High
₹596

₹ 585

52-w low
₹399.95

52-w high
₹686.3

585

Day's open
₹574.95
Previous close
₹575.35
VWAP
₹579.33
Lower price band
₹468
Upper price band
₹702

Today's Market Action

The last traded share price of Balaxi Pharmaceuticals Ltd was 585.00 up by 0.14% on the NSE. The total volume of shares on NSE and BSE combined was 3,584 shares. Its total combined turnover was Rs 0.21 crores.

Medium and Long Term Market Action

Balaxi Pharmaceuticals Ltd hit a 52-week high of 686.3 on 12-02-2024 and a 52-week low of 399.95 on 31-10-2023. The stock price of Balaxi Pharmaceuticals Ltd is up by 18% over the last one month. It is up by 9.36% over the last one year. Don't forget to check the full stock price history in the table below.

Fundamentals

Market Cap (Cr): 638
Book Value (₹):
Stock P/E:
Revenue (Cr):
Total Debt (Cr):

Face Value (₹):
Roce (%):
ROE (%):
Earnings (Cr):
Promoter’s Holdings (%):

EPS (₹):
Debt to Equity:
Dividend Yield (%):
Cash (Cr):

Mutual fund holdings and trends

FUND NAME	Quantity	Monthly Change (Qty)

Shareholding Pattern

Similar Stocks

Company	Price	Market Cap (Cr)	P/E

About

Data not available.

FAQ's

What is Share Price of Balaxi Pharmaceuticals Ltd?

What is the Market Cap of Balaxi Pharmaceuticals Ltd?

What is PE Ratio of Balaxi Pharmaceuticals Ltd?

What is PB Ratio of Balaxi Pharmaceuticals Ltd?

What is the CAGR of Balaxi Pharmaceuticals Ltd?

How to Buy Balaxi Pharmaceuticals Ltd Share?

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

Pros

Above Average Sustainable RoE
The company generates a sustainable return on equity greater than the expected cost of capital which implies that the underlying business can create and compound value over a period time due to it's ability to generate above average return on capital.
Asset Light Business
The company operates a great asset light business with a high Asset turnover ratio of 8.04. A high asset turnover ratio is a great driver of RoE and can improve shareholder returns. A relatively higher asset turnover ratio also will result in lower dilution as the business grows its revenues as earnings.

Cons

Poor Cash Flow Conversion
The business has very poor cash conversion ratio of only -30.11% of operating earnings getting converted into operating cash flow. This implies that increase in profits has not translated into higher cash flows for the business and incrementally higher investments in working capital which works negatively for shareholders.
Highly Cyclical Industry
The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
Poor Capital Allocation
The company has disproportionately high amount of assets locked up in working capital, cash and cash equivalents, loans and advances, etc to the extent of 78.79 % of total assets. This reflects poorly on the capital allocation strategy of the management which negatively impacts shareholder returns.
Poor Working Capital Cycle
The company has a very poor working capital cycle of 392 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.
Below Average Growth Rate
The company is estimated to grow at a slow pace which will impair wealth creation for shareholders.

Valuation Analysis

Margin of safety
(27/04/2024)

Margin of Safety Index: High

100.00%

100.00% People are bullish about Balaxi Pharmaceuticals Ltd

0.00%

0.00 % People are bearish about Balaxi Pharmaceuticals Ltd

What is your opinion about this Stock?

Historical Data

Date	Open	High	Low	Close	Volume	Daily Change %